nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Age-related differences in unmet needs and their predictors among adults with bladder cancer
|
Scharp, Danielle |
|
|
43 |
10 |
p. 595.e13-595.e24 |
artikel |
2 |
An overview of molecular testing in genitourinary malignancies
|
Roy-Chowdhuri, Sinchita |
|
|
43 |
10 |
p. 533 |
artikel |
3 |
An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer
|
Venkatesh, Arjun |
|
|
43 |
10 |
p. 596.e15-596.e21 |
artikel |
4 |
A population-level analysis on the association of cannabis use and urologic cancers
|
Davis, Ryan J. |
|
|
43 |
10 |
p. 598.e11-598.e16 |
artikel |
5 |
Application of RNA sequencing in urologic malignancies: Advances and challenges
|
Al-Obaidy, Khaleel I. |
|
|
43 |
10 |
p. 544-552 |
artikel |
6 |
Assessing the uptake of core outcome sets in randomized controlled trials for localized prostate cancer: A cross-sectional study
|
Wright, Carson L. |
|
|
43 |
10 |
p. 598.e17-598.e24 |
artikel |
7 |
Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma
|
Chow, Ryan D. |
|
|
43 |
10 |
p. 597.e1-597.e4 |
artikel |
8 |
Combination regimen of intravesical docetaxel, gemcitabine, and cisplatin in patients with BCG-unresponsive bladder cancer: clinical outcomes and genomic correlations
|
Joffe, Benjamin I. |
|
|
43 |
10 |
p. 594.e1-594.e7 |
artikel |
9 |
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma
|
Ishihara, Hiroki |
|
|
43 |
10 |
p. 598.e1-598.e10 |
artikel |
10 |
Concordance between clinical and pathologic staging of larger (cT2a-b) and more invasive (cT3a) renal cell carcinoma
|
Goodstein, Taylor |
|
|
43 |
10 |
p. 597.e5-597.e14 |
artikel |
11 |
Cover 2 - Masthead
|
|
|
|
43 |
10 |
p. IFC |
artikel |
12 |
Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy
|
Moon, Helen H. |
|
|
43 |
10 |
p. 594.e19-594.e29 |
artikel |
13 |
Editorial Board
|
|
|
|
43 |
10 |
p. i |
artikel |
14 |
Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis
|
Gazzoni, Gabriela |
|
|
43 |
10 |
p. 595.e1-595.e11 |
artikel |
15 |
Featured SUO fellow: Daniel S. Roberson, MD
|
Roberson, Daniel S. |
|
|
43 |
10 |
p. 585 |
artikel |
16 |
Genomic profiling of urological malignancies using tissue-based next generation sequencing
|
Alruwaii, Zainab I. |
|
|
43 |
10 |
p. 534-543 |
artikel |
17 |
Liquid biopsy testing in urological cancers: Focus on urine
|
Pisapia, Pasquale |
|
|
43 |
10 |
p. 553-564 |
artikel |
18 |
Mismatch repair deficiency testing for immune checkpoint inhibitor therapy in genitourinary malignancies
|
Yermakov, Leonid M |
|
|
43 |
10 |
p. 579-584 |
artikel |
19 |
Molecular testing in urinary cytology specimens: Current status and future directions
|
Chen, Fei |
|
|
43 |
10 |
p. 565-578 |
artikel |
20 |
National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database
|
Wallace, Brendan K. |
|
|
43 |
10 |
p. 596.e9-596.e13 |
artikel |
21 |
Sex-based differences in genetic alterations and immune checkpoint inhibitor response in urothelial bladder cancer
|
Kanumuambidi, Jean-Pierre (Trey) |
|
|
43 |
10 |
p. 594.e9-594.e18 |
artikel |
22 |
Table of Contents
|
|
|
|
43 |
10 |
p. ii-iii |
artikel |
23 |
The impact of prophylactic incisional negative pressure wound therapy on surgical site infection following open radical cystectomy
|
Roberson, Daniel S. |
|
|
43 |
10 |
p. 586-593 |
artikel |
24 |
Tumor profiling of advanced urothelial carcinoma: Comparative analysis based on social determinants of health
|
Hart, Lacey J. |
|
|
43 |
10 |
p. 596.e1-596.e7 |
artikel |
25 |
Vigorous physical activity as a potential environmental risk factor in renal medullary carcinoma
|
Shapiro, Daniel D. |
|
|
43 |
10 |
p. 597.e15-597.e23 |
artikel |